B and BIOAB Related Headlines
Go Back- Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
- Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
- Leqembi included in China's commercial insurance innovative drug list
- New data on lecanemab to be presented at CTAD conference
- Leqembi® approved for IV maintenance treatment in the United Kingdom
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- BioArctic signs $30 million deal with Novartis for brain drug technology
- BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
- Leqembi® (lecanemab) launched in the EU today
- Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
- BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile
- Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
- BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
B and BIOAB Related Press Releases
Go Back- Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
- Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
- Leqembi included in China's commercial insurance innovative drug list
- New data on lecanemab to be presented at CTAD conference
- Leqembi® approved for IV maintenance treatment in the United Kingdom
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
- Leqembi® (lecanemab) launched in the EU today
- Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
- BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile
- Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
- BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
